REG - OptiBiotix Health - License agreement with Tata Chemicals

OptiBiotix HealthAnnouncement

23/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231023:nRSW8588Qa&default-theme=true

RNS Number : 8588Q  OptiBiotix Health PLC  23 October 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

License agreement with Tata Chemicals

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that it has reached an agreement with Tata Chemicals Limited ("Tata
Chemicals") to incorporate its proprietary Fossence(®) into SlimBiome(®) and
LeanBiome(®) for the Indian market.

 

The agreement incorporates Tata's Fossence(®), a proprietary short chain
fructo-oligosaccharide ("FOS") into OptiBiotix's SlimBiome(®) and
LeanBiome(®) products for the Indian market. Fossence(®) will be a direct
replacement for the FOS used in SlimBiome(®) in other markets and brings
scientific substantiation of health benefits shown by  FOS in the Indian
market (see  Explore - Brochures, Whitepapers, Concept Notes & More |
Tata NQ (https://www.tatanq.com/resources/#scientific-reviews) ). Tata
Chemicals have approved the use of the Fossence(®) logo on products
containing SlimBiome(®) in India bringing a branded ingredient from a
well-known and trusted source to the attention of Indian consumers.

 

Tata Chemicals is a global science company active in industrial chemicals,
food and nutrition (Tata NQ), and agriculture listed on the Indian stock
Exchange. It is part of the Tata Group which employs over one million people
with annual revenues in 2022 of $300billion.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to report this
agreement with Tata Chemicals which creates the opportunity to bring products
containing Tatas proprietary Fossence(®) in SlimBiome(®) and LeanBiome(®)
to the Indian market. Tata Chemicals is one of India's leading suppliers of
food ingredients with many well-known and respected brands. Fossence's®
established health benefits with Indian consumers and its trusted brand
combined with SlimBiome's® strong science, clinical studies, and excellent
customer reviews will help reduce hunger and food cravings to support the
weight management efforts of India's 135 million obese men and women."

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFLEIRLIFIV